Switzerland's MoonLake Q3 net loss widens as R&D costs rise

MoonLake Immunotherapeutics

Wed 12:18

Overview
Switzerland biotech posted Q3 net loss as R&D expenses rose on milestone license fees
Company submitted Biologics License Application for sonelokimab to FDA for hidradenitis suppurativa
MoonLake ended Q3 with $498.5 mln in cash, expects runway to mid-2028

Outlook
Company expects FDA decision on sonelokimab BLA filing acceptance by end of Nov 2026
MoonLake anticipates potential US commercial launch of sonelokimab in H2 2027, if approved

Result Drivers
R&D EXPENSES - Co said expenses increased mainly due to milestone license fees tied to regulatory milestone associated with the expected acceptance of the Company's BLA submission 

Company press release: ID:nGNX8chbxc

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Loss Per Share
 
$0.93
 
Q3 Net Loss
 
$79.55 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 2 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for MoonLake Immunotherapeutics is $30.00, about 156.4% above its November 3 closing price of $11.70

Reuters Recommended Reads
Nov 3 - Switzerland's Oculis Q3 net loss widens as expenses rise
Nov 2 - Switzerland's CRISPR Therapeutics Q3 CASGEVY revenue jumps 30% sequentially
Nov 2 - FDA to review uniQure's Huntington's gene therapy, decision due on May 2027 

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)